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Background and purpose: The prognostic value of radiomics for non-small cell lung cancer (NSCLC)
patients has been investigated for images acquired prior to treatment, but no prognostic model has been
developed that includes the change of radiomic features during treatment. Therefore, the aim of this
study was to investigate the potential added prognostic value of a longitudinal radiomics approach using
cone-beam computed tomography (CBCT) for NSCLC patients.
Materials and methods: This retrospective study includes a training dataset of 141 stage I–IV NSCLC
patients and three external validation datasets of 94, 61 and 41 patients, all treated with curative
intended (chemo)radiotherapy. The change of radiomic features extracted from CBCT images was sum-
marized as the slope of a linear regression. The CBCT slope-features and CT-extracted features were used
as input for a Cox proportional hazards model. Moreover, prognostic performance of clinical parameters
was investigated for overall survival and locoregional recurrence. Model performances were assessed
using the Kaplan–Meier curves and c-index.
Results: The radiomics model contained only CT-derived features and reached a c-index of 0.63 for over-
all survival and could be validated on the first validation dataset. No model for locoregional recurrence
could be developed that validated on the validation datasets. The clinical parameters model could not
be validated for either overall survival or locoregional recurrence.
Conclusion: In this study we could not confirm our hypothesis that longitudinal CBCT-extracted radiomic
features contribute to improved prognostic information. Moreover, performance of baseline radiomic fea-
tures or clinical parameters was poor, probably affected by heterogeneity within and between datasets.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 136 (2019) 78–85 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Quantitative image analysis has been widely applied using
treatment planning computed tomography (CT) images acquired
at baseline prior to radiation treatment [1]. Investigation of the
prognostic and predictive performance of large amounts of quanti-
tative image features (i.e. radiomics) could eventually lead to the
discovery of biomarkers that can contribute to the development
of precision medicine [2–4]. The prognostic value of radiomic fea-
tures extracted from CT images has already been shown for non-
small cell lung cancer (NSCLC) [5–7]. Besides that, the potential
added value of CT imaging during treatment has been explored
for outcome prediction for both lung cancer and head-and-neck
cancer [8,9]. These during-treatment images were acquired in a
research setting and are generally not included in the clinical
workflow. Nonetheless, a large number of cone-beam CT (CBCT)
images are usually available, since these are acquired in clinical
practice prior to radiation treatment fractions for positioning veri-
fication purposes. This means that additional potential prognostic
information could be derived without extra patient burden. CBCT
images have previously been proposed to monitor tumor response
during treatment, either using radiomics [10–12] or simpler
metrics like volume, density and mean Hounsfield units (HU)
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[13–16]. Early prognostic information could aid in clinical decision
making regarding treatment adaption.
We hypothesize that the change of radiomic features might
contain additional information over baseline radiomic information,
since it would be possibly able to capture an early treatment
response. A previous study showed that radiomic features
extracted from cone-beam CT images acquired at the first radio-
therapy fraction contains similar prognostic performance for over-
all survival as baseline CT measurements [10]. Moreover, a recent
study showed that radiomic features acquired from CBCT images
do change more than the day-to-day variability during the course
of treatment [11]. Nevertheless, the prognostic value of these
changes in feature values has not yet been explored. Therefore,
in the current study we investigated the potential added prognos-
tic value of a longitudinal radiomics approach using CBCT images,
over the prognostic value of CT-extracted radiomic features, for
non-small cell lung cancer (NSCLC) patients.
Methods
Patients
Four patient cohorts from four different institutes were col-
lected retrospectively, consisting of 141 (Dataset 1), 94 (Dataset
2), 61 (Dataset 3) and 41 patients (Dataset 4). Two clinical end-
points were considered in this study: overall survival and locore-
gional recurrence, both measured from the start of radiotherapy
for all cohorts. Additionally, clinical parameters including age, gen-
der, TNM-stage, overall stage and histology were collected.
Detailed information about data collection, patients and exclusion
criteria can be found in Supplementary Material. The study was
approved by Maastro Clinic’s Institutional Review Board. Data col-
lection was approved by each institutional ethics committee.
Imaging
All patients in the cohort received a treatment planning CT
(pCT) image and at least four CBCT images acquired during the
course of radiotherapy. Moreover, the first available CBCT image
was acquired prior to the first (FX1) or second (FX2) radiotherapy
fraction. Patients were excluded from the study in case the field-of-
view (FOV) of one or multiple CBCT image(s) did not comprise the
entire primary tumor volume, which was the case for 19 patients
in Dataset 1. Also if the required minimum number of 4 CBCT
images was not available, patients were excluded. This was the
case for 5 patients of Dataset 1 and 1 patient of Dataset 3. Technical
details on the image acquisitions are presented in the Supplemen-
tary Material, as well as a histogram visualizing the timing of all
2154 analyzed CBCT images.
For all CBCT images, an intensity value correction was applied
before feature extraction, using a region of interest (ROI) in the
heart and a reference value from literature of 50 HU [17]. This is
identical to the first step of the correction procedure described in
more detail in [10].
Tumor segmentation
The treatment planning delineations of the primary gross tumor
volume (GTV) on the pCT images were used to define correspond-
ing tumor segmentations on all subsequent cone-beam CT images
with the deformable registration algorithm ‘Morphons’ of the open
source software REGGUI (http://openreggui.org). For Datasets 3
and 4, deformable registration in MIM (MIM Software Inc, Cleve-
land, OH, USA) was used. The use of MIM reduced the workload
by being able to register the images and adjust the contours in
one-go. We experienced similar performance for the deformable
registrations of both software packages and believe this did not
introduce a bias. Moreover, deformable registration was followed
by manual adjustments to improve the delineations by removing
spikes, loose pixels and irregularities or in case the registration
procedure was not able to properly register the images. All tumor
segmentations were checked and if needed manually adjusted by
experienced radiation oncologists. In Dataset 1, for two patients
the original GTV delineation contained two separate volumes and
it was not possible to define which one was the primary tumor.
Moreover, for 12 patients in Dataset 1, the tumor was indefinable
on the CBCT images due to infiltration, atelectasis or image blur-
ring. These 14 patients were therefore not included, resulting in
the final cohort of 141 patients. For Dataset 4, the tumor was inde-
finable on the CBCT images for 4 patients.
Feature extraction
A total of 2317 radiomic features were extracted from all pCT
and CBCT images included in the analysis, using in-house devel-
oped software programmed in Matlab 2014a (Mathworks, Natick,
MA). Additional information about the features and image pre-
processing can be found in Supplementary Material.
Cone-beam CT radiomics
Features were extracted from weekly or bimonthly CBCT scans
with at least four time points available for each patient throughout
the entire treatment. Due to the limited number of data points, lin-
ear regression was performed to estimate the development of the
radiomic features over time. Features values were first divided by
the initial value to obtain relative numbers to also include baseline
information. Then, a linear regression was performed and the slope
parameter of the linear regression was then used as a new CBCT
feature that captures the longitudinal information into one single
feature. The coefficient of determination (R2) was evaluated to ver-
ify the goodness of fit.
Feature selection
Feature selection was performed on the training dataset: Data-
set 1. The process consisted of several steps: (1) Feature clean-up,
(2) Selecting only changing CBCT features and calculate linear
regression slope, (3) Combine CBCT-slope feature set with pCT fea-
ture set and (4) Remove correlated features OR calculate principal
components. The steps are explained in further detail in Supple-
mentary Material and the resulting feature selection numbers are
provided in the Results section.
Model development and validation
As agreed upon prior to the analysis, three models were devel-
oped using only Dataset 1 as training dataset. The first model was
based on radiomics features itself (CBCT-slope and pCT). The sec-
ond model was based on the calculated principal components
(PCs) from the radiomic features. To investigate the clinical rele-
vance, the prognostic performance of radiomics was also compared
to those of clinical parameters: the input of the third model
included all available clinical parameters without radiomic fea-
tures. Interaction terms were not addressed in this study.
Penalized Cox proportional hazard models were developed
using a Least Absolute Shrinkage and Selection Operator (LASSO)
procedure [18]. A 10-fold cross validation procedure was repeated
200 times to stabilize the method and to find the optimal lambda
value with the smallest error. The performance of this Cox model
was evaluated without retraining the coefficients. The prognostic
index (PI), defined as
P
ibixi, was calculated for each patient. The
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distribution of the PIs on each dataset was evaluated to visualize as
suggested by Royston and Altman [19]. Moreover, the model fit
was evaluated by calculating estimating the regression coefficient
(‘calibration slope’) on the PI of the validation datasets, where a
slope of 1 would indicate that the discrimination in the validation
datasets is similar. Furthermore, the model misclassification was
tested by offsetting the original PI and running a Cox regression
on the covariates in the validation datasets. A significant p-value
of the joint test on all regression coefficients would indicate a lack
of fit of one or more variables.
The performance of Cox model was evaluated using the Kaplan–
Meier curves, split between a low-risk and high-risk group using
the median PI-value of all patients. A log-rank (LR) test was per-
formed to evaluate the significance of the split. Moreover, Harrell’s
concordance index (c-index) was calculated to assess the discrim-
inative power of the model, which is a measure that ranges from
0.5 (no discrimination) to 1.0 (perfect discrimination) [20].
The developed models on Dataset 1 were validated on Datasets
2, 3 and 4 or a combination of all validation datasets. The Kaplan–
Meier curves were evaluated as well as the c-index.
All statistics and analyses were performed using R (version
3.4.3).
Evaluation of the study design
The study design was evaluated using two methods: the Radio-
mics Quality Score (available online on www.radiomics.world) and
the TRIPOD classification [21,22]. The TRIPOD checklist for ‘‘Predic-
tion Model Development and Validation” was used to guide the
study and the ‘‘TRIPOD Adherence data extraction checklist” was
used to calculate a score (0–100%) for the final study (both avail-
able online on www.tripod-statement.org).
Results
The patient characteristics of the final cohorts are shown in
Table 1. Missing data in Dataset 1 was corrected using mean impu-
tation: for 1 patient the WHO status was unknown, for 7 patients
the smoking status was unknown and for 28 patients the FEV1
was unknown. A comparison of the overall survival and locore-
gional recurrence is shown in Fig. 1.
A summary of the feature selection workflow is provided in
Fig. 2. Feature selection resulted in a final set of 283 radiomic fea-
tures, consisting of 88 CBCT-slope features and 195 CT features. A
total of 50 principal components described 95% of the variance in
the data and were subsequently used as input for the modeling.
The median of the mean R2 values calculated per feature by aver-
aging over all patients, showing the goodness of fit of the linear
regression for acquiring the CBCT-slope features, was 0.40 ± 0.05
(median ± SD).
Three models were developed for both overall survival and
locoregional recurrence, using different input variables: (1) radio-
mic features (models 1.1 and 1.2), (2) principal components (mod-
els 2.1 and 2.2) and (3) clinical parameters (models 3.1 and 3.2).
Model 1.1 was developed to predict overall survival and resulted
in a three-feature model containing only CT features. Model 1.2
for locoregional recurrence resulted in a six-feature model, consist-
ing of three CBCT-slope features and three CT features. Models 2.1
and 2.2 could not be build, as no prognostic features could be iden-
tified for either overall survival or locoregional recurrence using
the principal components as input. Model 3.1 included six clinical
features to predict overall survival. Model 3.2 is a three-feature
clinical model to predict locoregional recurrence.
All models with the feature’s respective b-coefficients, plus the
median and range of the feature values in Dataset 1 (which was
used for training), are summarized in Table 2. Explanations of all
features in these models can be found in Supplementary Material.
The distribution of the PIs, the calibration slope of the PI and the
joint test on all regression coefficients are also shown in Supple-
mentary Material. The C-indices of all identified prognostic models
are shown in Fig. 3. The clinical model contained parameters which
were not available for Dataset 4 (WHO performance status), so this
model was only validated in Datasets 2 and 3. The Kaplan–Meier
curves for the radiomics model predicting overall survival (model
1.1) are shown in Fig. 4. The Kaplan–Meier curves for model 1.2,
for predicting locoregional recurrence, are shown in Supplemen-
tary Material.
The study design was evaluated using the Radiomics Quality
Score (RQS) and the TRIPOD statement. We achieved an RQS of
53.8% as feature reduction was applied, three validation datasets
were available and a clinical model was investigated. On the other
hand, there was no phantom study involved, the correlation with
underlying biology was not investigated, the data were not avail-
able from a prospective study registered in a trial database and
no cost-effective analysis was performed. On the other hand, fea-
ture reduction was performed and three validation datasets were
available to validate the model without retraining and without
adaption of the cut-off value. Moreover, the radiomics model per-
formance was compared to that of clinical parameters, including
TNM-stage and volume, which are commonly seen as the gold
standard. The TRIPOD checklist for Prediction Model Development
and Validation Scoring [21,22], using the TRIPOD items for ‘Devel-
opment and external validation (of the same model)’, reached a
score of 81%. The latter can be found in Supplementary Material.
Discussion
The aim of this study was to investigate the complementary
prognostic value of CBCT radiomic features for overall survival
and locoregional recurrence of NSCLC patients. We hypothesized
that the change of radiomic features contains additional informa-
tion over baseline radiomic information. To this extent, models
were developed using CBCT-slope and planning CT-derived radio-
mic features. Model performances were compared to that of a
model including solely clinical parameters.
For the first models, selected CBCT-slope and pCT features were
used as input for LASSO. A prognostic model was identified for
overall survival, which contains three CT based radiomic features.
The performance of the model was average (c-index 0.63 [95% C.
I. 0.57–0.69]), but it could be validated on Dataset 2 (c-index
0.59 [95% C.I. 0.54–0.65]) and also on the combined set of Datasets
2, 3 and 4. A model developed by Fave et al. [9] containing clinical
parameters, baseline CT-radiomic features and delta-CT radiomic
features found a c-index 0.675, but no external validation was pre-
sent and weekly CT imaging acquired in a research setting was
used for this study. For locoregional recurrence, six radiomic fea-
tures were selected including three CBCT-slope features and three
CT features. This model did not reach significance in any of the val-
idation datasets. Also in the study of Fave et al. [9], no delta CT fea-
tures were significant predictors for locoregional recurrence.
For the second models, principal components were used as
input for LASSO. For both overall survival and locoregional recur-
rence, no prognostic models could be identified.
The third and last models, containing clinical parameters,
achieved a c-index of 0.62 for overall survival and 0.69 for locore-
gional recurrence on Dataset 1. Both models did not validate on
either Dataset 2, Dataset 3 or a combination of both.
Previous studies have shown that a four-feature radiomics
model derived from CT images has prognostic value for NSCLC
patients. Also, a previous study showed that this model could also
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be validated using CBCT images acquired prior to the first radio-
therapy fraction [10]. Therefore, we also investigated the perfor-
mance of a previously developed radiomic signature [5] during
treatment. The c-index was 0.59 for all datasets combined, which
was not significantly different compared to the validation perfor-
mance in other studies [5,10,23]. The performance of the signature
on CBCT images acquired during radiation treatment shows that
the signature is robust over time, but the prognostic value does
not improve at later time points (data not shown).
Complementary prognostic value of longitudinal CBCT radiomic
features could not be shown in this study. No CBCT-slope features
were selected by LASSO to predict overall survival. For locoregional
recurrence, CBCT-slope features were selected, but the model did
not validate on any of the validation datasets. The lack of prognos-
tic value of CBCT-slope features can be caused by several factors.
First of all, the slope surrogate might not be the best method to
use for representing CBCT features changing over time. Only a
few data points per patient were included to estimate the slope,
since the GTV segmentations on the CBCT were time-consuming
as they needed manual verification and adjustment. Due to this
limited number of data points available, the slope is sensitive to
outliers. Potentially, automatic segmentations, for instance atlas-
based methods or deep learning, could improve this methodology
[24,25]. Besides the uncertainty in the slope parameters due to the
limited number of data points, it is possible that the development
of CBCT extracted radiomic features over time is not linear. A more
advanced model to represent the behavior of radiomic features
over time might be more appropriate (e.g. a quadratic model or
Table 1
Patient characteristics for all datasets. The dashed numbers indicate to which dataset the respective variable was significantly different (p < 0.05).
Dataset 1
(n = 141)
Dataset 2
(n = 94)
Dataset 3
(n = 61)
Dataset 4
(n = 41)
Age 3,4 3 1 1,2
Range (median) 45–86 (70) 42–83 (68) 39–83 (65) 41–85 (62)
Mean ± SD 68.6 ± 9.6 67.0 ± 8.5 64.2 ± 9.3 62.3 ± 10.7
Gender 4 4 1,2
Male 86 (60.6%) 45 (47.9%) 48 (78.7%) 26 (63.4%)
Female 56 (39.4%) 49 (52.1%) 13 (21.3%) 15 (36.6%)
WHO performance status 2,3 1,3 1,2
0 16 (11.3%) 27 (28.7%) 42 (68.8%)
1 96 (68.1%) 53 (56.4%) 15 (24.6%)
2 24 (17.0%) 14 (14.9%) 4 (6.6%)
3 4 (2.8%) 0 (0%) 0 (0%)
Stage
I 12 (8.5%) 4 (4.3%) 0 (0%) 2 (4.9%)
II 15 (10.6%) 7 (7.4%) 3 (4.9%) 4 (9.7%)
IIIa 44 (31.2%) 50 (53.2%) 37 (60.7%) 25 (61.0%)
IIIb 55 (39.0%) 33 (35.1%) 21 (34.4%) 10 (24.4%)
IV 15 (10.6%)* 0 (0%) 0 (0%) 0 (0%)
Histologyy
Adenocarcinoma 37 (26.2%) 34 (36.2%) 34 (55.7%) 14 (34.1%)
Squamous cell carcinoma 60 (42.6%) 42 (44.7%) 22 (36.1%) 15 (36.6%)
Large cell carcinoma 5 (3.5%) 5 (5.3%) 3 (4.9%) 3 (7.3%)
Undifferentiated 0 (0%) 6 (6.4%) 0 (0%) 0 (0%)
Not otherwise specified 39 (27.7%) 7 (7.4%) 2 (3.3%) 9 (22.0%)
GTV (cm3)
Range (median) 0.61–341 (38) 2.1–397 (38) 1.5–425 (36) 1.7–415 (55)
Mean ± SD 62.3 ± 70.6 70.2 ± 74.6 72.3 ± 93.0 90.1 ± 72.3
Concurrent chemotherapy
Yes 90 (63.8%) 63 (67.0%) 35 (57.4%)
No 51 (36.2%) 31 (33.0%) 26 (42.6%)
Interval CT–RT (Days) 2,3,4 1,3 1,2 1
Range (median) 3–16 (7) 5–21 (11) 6–39 (13) 6–21 (13)
Mean ± SD 7.2 ± 1.6 10.9 ± 2.4 15.6 ± 7.7 12.7 ± 3.9
Received RT dose (Gy) 2,3,4 1,3,4 1,2,4 1,2,3
Range (median) 45–76 (69) 60–66 (66) 60–70 (70) 52–67.5 (66)
Mean ± SD 66.4 ± 5.6 64.3 ± 2.7 68.5 ± 3.1 65.2 ± 3.2
Radiotherapy schedule 2,3,4 1 1 1
30–35 * 2 Gy (daily) 0 (0%) 94 (100%) 61 (100%) 41 (100%)
30  1.5 Gy (twice daily) + 5–12  2 Gy (daily) 78 (54.9%) 0 (0%) 0 (0%) 0 (0%)
23–24  2.75 Gy (daily) 28 (19.7%) 0 (0%) 0 (0%) 0 (0%)
38–42  1.8 Gy (daily) 26 (18.3%) 0 (0%) 0 (0%) 0 (0%)
Other 10 (7.0%) 0 (0%) 0 (0%) 0 (0%)
Overall survival (year)
Median [range] 2.0 [0.1–4.8] 1.7 [0.1–9.8] 2.8 [0.4–7.7] 1.8 [0.4–6.5]
Events at time of analysis
Survival 91 84 32 31
Follow-up (year) 2,3 1,3,4 2,4 1,2,3
Median [range] 3.0 [0.2–4.8] 8.6 [6.6–9.8] 3.4 [1.1–7.7] 5.7 [5.3–6.5]
* This group of patients is treated with curative intent and has similar prognosis and the stage III patients.
y For histology, it was investigated whether the number of adenocarcinoma and squamous cell carcinoma patients was significantly different between the datasets.
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polynomial). However, the limited number of available data points
in combination with a model with more degrees of freedom would
have resulted in overfitting and most likely a false-positive result.
Furthermore, it is also possible that the slope features contain no
prognostic information, whereas the absolute difference between
the feature values of two CBCT scans does have prognostic value.
In a recent study it was shown that a large number of features
change more than expected by chance in week 3 and week 4 of
treatment [11], but this was not yet related to outcome informa-
tion. The lack of prognostic value of current CBCT features may also
be influenced by the low image quality of cone-beam CT. Although
a previous study showed that a batch of radiomic features are
interchangeable between planning CT and cone-beam CT, other
features might be subject by high levels of noise. Several efforts
are being made for improving the image quality of CBCT images,
e.g. using artifact reduction techniques, hardware developments,
improvement of 4D imaging or the implementation of iterative
reconstruction methods [26–28]. In this study three different CBCT
systems were involved: Varian Truebeam (Dataset 1), Elekta Syn-
ergy (Datasets 2 and 4) and Varian Clinac (Dataset 3). The image
quality of these three systems differs substantially, which could
have affected the lack of validation performance for the model con-
taining CBCT slope features. Furthermore, the CBCT images ana-
lyzed in the current study are free-breathing, which for lung
tumors causes a blurring of the region of interest. Considering all
these factors, it is likely that (some of) these factors hamper the
discovery of prognostic value in CBCT-extracted radiomic features.
Once the image quality of CBCT is improved and automatic
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Fig. 1. Kaplan Meier curves showing the overall survival (A) and locoregional
recurrence (B) of all datasets.
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segmentation methods are developed, it would be interesting to
redo the analysis.
A factor that could have influenced the validation performance
of model 1.2 (containing CBCT-slope features to predict locore-
gional recurrence) is the software package used to perform the
deformable registration to transfer the GTV contour of the pCT
onto the CBCT images: a different software package was used in
Datasets 1 and 2 than in Datasets 3 and 4. Although we have not
experienced a difference between the two methods and the radia-
tion oncologist manually verified all contours, this could poten-
tially have resulted in a systematic bias in the data. Nevertheless,
this model also did not validate on Dataset 2, for which the same
software package was used as in training Dataset 1. Moreover, this
does not explain the lack of validation performance of the models
containing only pCT-features or clinical parameters.
In general, models based on (pre)treatment imaging or param-
eters do most likely not contain enough information to more accu-
rately predict a future event like death. Treatment changes, and in
particular second-line or third-line therapies, have an enormous
effect on overall survival. Another explanation for the poor valida-
tion performance could be the intra- and inter-dataset heterogene-
ity and the limited sample size of the validation datasets, which are
Table 2
Model features with corresponding model coefficients and indication the median and range of the feature values in training Dataset 1. Model 1.1 and model 3.1 were developed to
predict overall survival and model 1.2 and model 3.2 were developed to predict locoregional recurrence. For models 2.1 and 2.2, no prognostic features were identified. Feature
definitions are presented in Supplementary Material.
Model b-coefficients Feature names Median feature value [range]
Models 1.1 and 1.2: radiomics features for overall survival and locoregional recurrence, respectively
Model 1.1 4.25  103 CT_LoG_sigma_2_5_mm_3D_pos_IH_mode 1 [1–20]
9.66  104 CT_LocInt_peakLocal 882.4 [414.5–1442.7]
1.96  104 CT_Wavelet_LLL_GLCM_inverseVar 0.30 [0.13–0.47]
Model 1.2 3.12  103 CT_LoG_sigma_2_5_mm_3D_pos_IH_maxGradI 12 [1–29]
0.0255 CT_LoG_sigma_5_5_mm_3D_IH_p10 11 [2.8–22]
0.665 CT_Wavelet_HHH_Stats_median 0.011 [1.28 to 0.84]
11.0 CBCT-slope_Wavelet_HHL_GLCM_maxCorr 0.0033 [0.0088 to 0.021]
2.42 CBCT-slope_Wavelet_HLH_GLCM_infoCorr2 0.0035 [0.0070 to 0.022]
3.46 CBCT-slope_Wavelet_HLL_GLCM_inverseVar 0.0022 [0.020 to 0.016]
Models 2.1 and 2.2: principal components for overall survival and locoregional recurrence, respectively
No models could be identified
Models 3.1 and 3.2: clinical variables for overall survival and locoregional recurrence, respectively
Model 3.1 0.424 WHO 2 Dummy variables
0.0567 Concomitant
0.453 Stage II
0.165 Stage IIIa
0.121 Histology (other)
0.178 Histology (squamous cell)
Model 3.2 0.122 WHO 1 Dummy variables
0.223 Stage IIIa
0.558 Histology (squamous cell)
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Fig. 3. C-indices of the prognostic models identified for overall survival (left) and locoregional recurrence (right). The combination was either Datasets 2, 3 and 4 (model 1.1)
or Datasets 2 and 3 (models 1.2, 3.1 and 3.3). Models 1.1 and 1.2 contain only radiomic features and models 3.1 and 3.2 contain only clinical parameters. For models 2.1 and
2.2 no prognostic features could not be identified.
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common phenomena of retrospective (multicentric) studies.
Comparing patient characteristics and scanner parameters show
that the datasets are not much alike, which makes it difficult for
a model to perform well on the external dataset. Locoregional
recurrence free survival in Dataset 2 is worse compared to the
other datasets, which might be caused by an earlier detection of
tumor recurrence because of the use of PET in the follow-up pro-
gram in this institution [29]. Overall survival is better in Dataset
3, in which a larger number of patients have WHO performance
status 0 compared to the other datasets. Moreover, radiotherapy
schedule, age and imaging protocols differed between datasets.
Several validation measures were evaluated to investigate the
potential cause for the fact that the developed models could not
be validated on the validation datasets. The distribution of the
prognostic indices for the radiomics model which was developed
for overall survival is comparable for all datasets. Moreover, the
calibration slope of the PI was not significantly different from 1
for any of the validation datasets. Furthermore, the joint test on
all coefficients was not significant, showing that there is no
evidence for a lack of fit. These results show that model covariates
and coefficients are comparable in the validation datasets, which
indicates that it is most likely that the lack of validation is a result
of the small cohort sizes. We recommend to perform future studies
on larger, more homogeneous datasets.
In this study we could not confirm our initial hypothesis that
longitudinal radiomic features extracted from CBCT images
contribute to improved prognostic information. Nevertheless, the
model developed for overall survival containing only CT features,
could be validated in one external dataset and also on a combina-
tion of all three external validation datasets. On the other side, val-
idation of the models containing only clinical parameters showed
poor performance, which indicates that there is still a lack of repro-
ducible prognostic models for outcome prediction in NSCLC.
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